Bruno Paiva, PhD^1*, Noemi Puig, MD, PhD^2*, Paula Arana^3*, Teresa Cedena^4*, Lourdes Cordon^5*, Maria Belen Vidriales, MD, PhD^2*, Norma C Gutierrez^6*, Joaquin Martinez-López, MD.PhD^7*, Miguel T Hernandez^8*, Ana Isabel Teruel, MD^9*, Mercedes Gironella^10*, M Asuncion Echeveste^11*, Laura Rosiñol, MD PhD^12*, Rafael Martinez, MD^13*, Albert Oriol, MD PhD^14*, Javier De La Rubia^15*, Joan Blade, MD PhD¹², Juan Jose Lahuerta^16*, Maria-Victoria Mateos¹⁷ and Jesus San Miguel, MD PhD^18*

¹Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain
²Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
³Clinica Universidad de Navarra, Pamplona, Spain
⁴Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
⁵Hospital Universitario La Fe, Valencia, Spain
⁶Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Salamanca, Spain
⁷Hematology, Hospital 12 de Octubre, Madrid, Spain
⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
⁹Hospital Clinico de Valencia, Valencia, Spain
¹⁰Hospital Universitari Vall dHebron, Barcelona, Spain
¹¹Hospital Universitario Donostia, San Sebastian, Spain
¹²Hospital Clinic de Barcelona, Barcelona, Spain
¹³Hospital Clinico, Madrid, Spain
¹⁴Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
¹⁵H.U.P. La Fe, Valencia, Spain
¹⁶Hospital 12 de Octubre, Madrid, Spain
¹⁷Hematology Department, University Hospital of Salamanca/IBSAL, Salamanca, Spain
¹⁸Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain

Niels Weinhold, PhD^1*, Shweta S. Chavan, PhD^1*, Christoph Heuck, MD¹, Owen W Stephens, PhD^1*, Ruslana Tytarenko^1*, Michael Bauer^1*, Erich Allen Peterson, PhD, BS, MS^1*, Timothy C. Ashby^1*, Tobias Meissner^2*, Caleb K. Stein, MS^1*, Donald Johann, MD, MS¹, Sarah K. Johnson, PhD¹, Shmuel Yaccoby, PhD¹, Joshua Epstein, DSc¹, Frits van Rhee, MD, PhD¹, Maurizio Zangari, MD¹, Carolina Schinke, MD^1*, Sharmilan Thanendrarajan, MD¹, Faith E Davies, MD¹, Bart Barlogie, MD, PhD¹ and Gareth J Morgan, MD PhD¹

¹Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
²Department of Molecular and Experimental Medicine, Avera Cancer Institute, La Jolla, CA

Nikhil C. Munshi, MD^1,2, Stephane Minvielle^3*, Yu-Tzu Tai, PhD¹, Mariateresa Fulciniti⁴, Mehmet K Samur, Ph.D^4*, Paul G. Richardson, MD⁴, Michel Attal⁵, Philippe Moreau^3*, Florence Magrangeas^3*, Kenneth C Anderson⁴, Malek Faham, MD, PhD⁶ and Herve Avet-Loiseau^5*

¹Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA
²Boston Veterans Administration Healthcare System, West Roxbury, MA
³Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche Thérapeutique de l’Université de Nantes (IRT-UN), Nantes, France
⁴The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Unité de Génomique du Myélome, CHU Rangueil, Toulouse, France
⁶Adaptive Biotechnologies Corp., South San Francisco, CA

Rakesh Verma, PhD¹, Till Strowig, PhD^2*, Rituparna Das, PhD^1*, Srinivas Koduru, PhD^1*, Anja Hafemann, PhD^3*, Stephanie Hopf^3*, Mehmet H. Kocoglu, MD⁴, Chiara Borsotti, PhD^5*, Lin Zhang^1*, Andrew R Branagan, MD¹, Elizabeth Eynon, PhD^3*, Markus Manz, MD⁶, Richard Flavell, Ph.D^3* and Madhav V Dhodapkar, MD¹

¹Yale Cancer Center, New Haven, CT
²Microbial Immune Regulation junior research group, Helmholtz Centre for Infection Research, Braunschweig, Germany
³Department of Immunobiology, Yale School of Medicine, New Haven, CT
⁴Department of Medicine and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
⁵Department of Hematology, University Hospital Zurich, Zurich, Switzerland
⁶Division of Hematology, University Hospital Zurich, Zurich, Switzerland

Yuji Mishima, PhD^1*, Bruno Paiva, PhD^2*, Jiantao Shi^3*, Mira Massoud^4*, Salomon Manier, MD¹, Ludmila Flores^4*, Adriana Perilla-Glen, MBA^1*, Yosra Aljawai, MSc^1*, Daisy Huynh, BS, MS^1*, Satoshi Takagi, PhD¹, Aldo M Roccaro, MD, PhD¹, Antonio Sacco, BS^1*, Diego Alignani^2*, Maria Victoria Mateos^5*, Joan Bladé, MD⁶, Juan Jose Lahuerta^7*, Paul G. Richardson, MD¹, Jacob P. Laubach, MD⁸, Robert L. Schlossman, MD⁸, Kenneth C Anderson, MD¹, Nikhil C. Munshi, MD¹, Felipe Prosper, MD⁹, Franziska Michor, PhD^3*, J.F. San Miguel⁹ and Irene M. Ghobrial, MD¹⁰

¹Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Clínica Universidad de Navarra, Pamplona, Spain
³Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
⁵Hematolgy, Hospital Universitario de Salamanca, Salamanca, Spain
⁶Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
⁷Hospital 12 de Octubre, Madrid, Spain
⁸Dana-Farber Cancer Institute, Boston, MA
⁹Clinica Universidad de Navarra, Pamplona, Spain
¹⁰Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Carolina Terragna, PhD^1*, Marina Martello, PhD^1*, Mauro Procacci^1*, Flavio Mignone^2*, Annalisa Pezzi, PhD^1*, Barbara Santacroce^1*, Lucia Pantani, MD^1*, Igor Saggese^2*, Torsten Haferlach³, Elena Zamagni^1*, Enrica Borsi, PhD^1*, Paola Tacchetti, MD^1*, Beatrice A Zannetti, MD^1*, Serena Rocchi, MD^1*, Katia Mancuso, MD^1*, Flores A Dico^1*, Giovanni Martinelli, MD, PhD¹ and Michele Cavo^1*

¹DIMES - Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology, University of Bologna, Bologna, Italy
²Dipartimento Scienze e Innovazione Tecnologica, Università Piemonte Orientale, Alessandria, Italy
³MLL Munich Leukemia Laboratory, Munich, Germany